On the same basis and measured in value in 1999, Merck had a share of [around 55 %] of the world market and a respective share of [around 70 %] in the Community. The estimated shares of Aventis were [around 45 %] of the world market and [around 30 %] in the EEA market(9).
Recital 8, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002